CINECA IRIS Institutional Research Information System

NICOLINI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.377
EU - Europa 3.702
AS - Asia 1.752
AF - Africa 140
OC - Oceania 8
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 15.984
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.000
IT - Italia 1.194
CN - Cina 1.038
SE - Svezia 633
BG - Bulgaria 563
CA - Canada 373
UA - Ucraina 363
DE - Germania 271
TR - Turchia 258
FI - Finlandia 225
SG - Singapore 189
VN - Vietnam 175
GB - Regno Unito 168
CH - Svizzera 142
CI - Costa d'Avorio 116
HK - Hong Kong 52
RU - Federazione Russa 41
FR - Francia 28
IN - India 22
SN - Senegal 21
BE - Belgio 16
AT - Austria 10
CZ - Repubblica Ceca 10
AU - Australia 8
GR - Grecia 8
NL - Olanda 8
IR - Iran 5
DK - Danimarca 4
HU - Ungheria 4
IE - Irlanda 3
RO - Romania 3
TH - Thailandia 3
BR - Brasile 2
ES - Italia 2
EU - Europa 2
IL - Israele 2
KR - Corea 2
MU - Mauritius 2
PL - Polonia 2
TW - Taiwan 2
BD - Bangladesh 1
DO - Repubblica Dominicana 1
GT - Guatemala 1
HR - Croazia 1
ID - Indonesia 1
JP - Giappone 1
LT - Lituania 1
LU - Lussemburgo 1
MX - Messico 1
NI - Nicaragua 1
RS - Serbia 1
SA - Arabia Saudita 1
UY - Uruguay 1
ZA - Sudafrica 1
Totale 15.984
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.423
Ann Arbor 1.238
Chandler 966
Fairfield 918
Houston 883
Sofia 563
Ashburn 486
Jacksonville 483
Milan 463
Seattle 373
Beijing 368
Ottawa 366
Wilmington 354
Cambridge 336
New York 322
Nanjing 259
Izmir 257
Princeton 229
Lawrence 220
Medford 214
Des Moines 165
Bern 139
Abidjan 116
Singapore 104
Dearborn 101
Nanchang 89
Jüchen 75
Dong Ket 71
Florence 60
Serra 55
Kunming 53
Hong Kong 50
San Diego 43
Shenyang 42
Hebei 34
Ogden 34
Boulder 33
Rome 33
Tianjin 31
Chicago 30
Falls Church 28
Redwood City 23
Hefei 22
Dakar 21
Hangzhou 21
Pune 21
Changsha 20
Lancaster 20
Jiaxing 19
Boardman 18
Los Angeles 18
Norwalk 18
Düsseldorf 17
Orange 17
Auburn Hills 16
Brussels 16
Pisa 14
Lanzhou 13
London 13
Jinan 12
Washington 12
Changchun 10
Vienna 10
Anguillara Sabazia 9
Detroit 9
Frankfurt am Main 9
Guangzhou 9
Nettuno 8
Verona 8
Grafing 7
Council Bluffs 6
Genoa 6
Indiana 6
Kent 6
Marseille 6
Phoenix 6
Lucca 5
Redmond 5
Shanghai 5
Simi Valley 5
Tappahannock 5
Chongqing 4
Olomouc 4
Prague 4
Viareggio 4
Amsterdam 3
Bremen 3
Chengdu 3
Copenhagen 3
Fuzhou 3
Jinhua 3
Limbiate 3
Ningbo 3
North York 3
Walnut 3
Wenzhou 3
Ardabil 2
Athens 2
Atina 2
Buffalo 2
Totale 12.655
Salva come PNG Salva come JPEG
Nome #
Effect of pulsed electromagnetic field stimulation on knee cartilage, subchondral and epyphiseal trabecular bone of aged Dunkin Hartley guinea pigs 148
Molecular markers in breast cancer: no longer a “free” run from laboratory to the clinic 148
Early diagnosis and treatment of breast cancer relapses 131
T cell-mediated immunity, eosinophils, sIL-2R, neopterin and interleukins 4, 6, 10, 12 in metastatic renal and colorectal cancer patients (pts) cyclically treated with low subcutaneous (s.c.) rIL-2 128
A rationale non-invasive schedule with tumor markers and instrumental exsaminations for “early” detection of bone metastases in breast cancer 122
Bone scintigraphy and tumor markers in the post-operative follow-up of breast, colorectal, prostate and renal cancer 122
Manual lymphatic drainage for chronic post-mastectomy lymphoedema treatment 119
Are risk factors common to thyroid cancer and nodule? A forty years observational time-trend study 119
Prolonged survival by “early” salvage treatment of breast cancer patients: a retrospective six year study 118
An iron regulatory gene signature in breast cancer: More than a prognostic genetic profile? 118
A meta-analysis of the performance of serum tumour markers levels for early signalling distant metastases during post-operative follow-up of disease-free breast cancer patients 116
Stem Cells: Their Role in Breast Cancer Development and Resistance to Treatment. 114
Accuracy of an individual reference limit (IRL) during intensive post-operative monitoring of disease-free breast cancer patients with serum CEA-TPA-CA15.3 tumor marker (TM) panel 113
Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse. 112
Quantification of Blood Dendritic Cells in Colorectal Cancer Patients During the Course of Disease 111
Tumor markers increase the diagnostic accuracy of skeletal metastases in breast cancer patients 107
Criteria to use serum tumour marker levels for early signalling distant metastases durino post-operative follow-up of disease-free breast cancer patients: laboratori and clinical aspects. 107
A rational non invasive schedule with tumor markers, bone scanning (BS) and "aimed" computed tomography (CT) or skeletal x - ray for "early" detection of bone metastases in breast cancer 105
Cytometric evaluation of mitogenic proliferation response to phytohemagglutinin (PHA) and NK cytotoxic activity of peripheral blood lymphocytes in patients (pts) mastectomized for breast cancer 104
Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. 104
Pilot study with subcutaneous (s.c.) low dose rIL-2 cyclically given in addition to 5-FU and leucovorin (LV) in metastatic colorectal cancer 103
Postoperative monitoring of breast cancer patients with tumor markers 102
T-cell mediated immunity (CMI) and B lymphocytes in breast cancer patients after mastectomy 102
Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor biology 101
A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect 100
A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect 100
Evaluation of CEA, TPA, Ca 15.3, Ca 549 and TPS in the monitoring of metastatic breast cancer 97
Urinary markers of bone resorption in breast cancer patients 97
Reducing radiological imaging during post-operative monitoring of breast cancer patients with serum CEA-TPA-CA15.3 tumor marker (TM) panel and an individual reference limit (IRL) 97
Additional 5-FU-LV significantly increases survival in gastrointestinal cancer 97
Lymphopressotherapy in chronic postmastectomy lymphedema 95
Cell mediated immunity (CMI) in non relapsed breast cancer patients 94
Atherosclerosis and cancer: common pathways on the vascular endothelium 94
CEA, TPA, GICA, CA 72-4 and CA 195 and their associations in the post-operative follow-up of colorectal cancer 93
Cell mediated immunity in disease free breast cancer patients 93
Impact on survival of "early" detection of colorectal cancer relapses with tumor markers 92
Large needle aspiration biopsy histology for the preoperative selection of the palpable thyroid nodule diagnosed by FNA cytology as microfollicular nodule, microfollicular nodule with atypical cells or suspected cancer 92
Stem cells: their role in breast cancer development and resistance to treatment. 92
Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients 91
Cell mediated immunity (CMI) in breast cancer patients at the relapse 90
Comparison of Ca 549 and TPS usefulness with CEA, TPA and Ca 15.3 in the post-operative follow-up of breast cancer patients 90
Uselfulness of serum CEA, GICA and ferritin measurement in the postoperative follow-up of renal cancer 90
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. 90
Defining the critical hurdles in cancer immunotherapy. 90
Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial 90
Osteoporosis and biomaterial osteointegration 90
From the bench to the bedside. Galectin-3 immunodetection for improving the preoperative diagnosis of the follicular thyroid nodules 90
Cytometric evaluation of mitogenic proliferation response to phytohemagglutinin and NK cytotoxic activity of peripheral blood lymphocytes in patients mastectomized for breast cancer 89
Tumoral markers in the kidney cancer: preliminary results 89
Large needle aspiration biopsy (LNAB) of palpable thyroid nodules refines the two FNA cytological diagnoses of microfollicular nodule and suspected cancer 89
Aspiration needle biopsy refines preoperative diagnosis of thyroid nodules defined at fine needle aspiration as microfollicular nodule 89
Advanced breast cancer: an update and controversies on diagnosis and therapy 89
Cancer stem cells: perspectives of new therapeutical approaches for breast cancer 89
Comparison Between Two Different Dynamic Methods for Evaluating CEA-TPA-CA15.3 Tumor Marker ™ Panel Specificity in the Post-Operative Follow-up of Disease-Free Breast Cancer Patients: Preliminary Results 89
Bioabsorbable scaffold for in situ bone regeneration. 89
null 88
Comparison between hydroxyproline (OHP) and deoxypyridinoline (DPD) in the detection of bone metastases in patints with breast cancer and benigne pathology 86
Microcirculation in chronic post-mastectomy lymphoedem 86
Therapy following “early” detection of relapse with the CEA-TPA-CA15.3 panel after mastectomy prolongs overall survival 86
A rationale follow-up with CEA-TPA-CA15.3 tumor marker panel strongly decreases the conventional instrumental examinations to monitor metastatic breast cancer patients 85
Prognostc value of tissue vascular endothelial growth factor in primary breast cancer 85
Subcutaneous (s.c.) low dose rIL-2 cyclically given increases the response rate (RR) and prolongs the response to 5-FU and LV of metastatic colorectal cancer patients (pts): an update of results 85
First Line Salvage Hormone Immunotherapy in Endocrine-Dependent Metastatic Breast Cancer 85
CEA, TPA, GICA, CA 72-4 and CA 195 in the post-operative follow-up of colorectal cancer 84
Usefulness of serum NSE and S-100 protein in patients with malignant melanoma: preliminary data 84
Serum levels of T-lymphocyte subpopulations, eosinophils, sIL-2R, neopterin and IL-4, IL-6, IL-10, IL-12 in metastatic renal and colorectal cancer patients (pts) cyclically treated with low subcutaneous (s.c.) rIL-2 84
TSH levels are affected by time of blood sampling in untreated euthyroid goitrous patients. 83
Von Willebrand’s factor mediates the adherence of human tumoral cells to human endothelial cells and ticlopidine interferes with this effect 83
Prognostic indices of overall survival (OS) and response to TAM and MAP in metastatic breast cancer patients 82
Comparison between two groups of breast cancer patients submitted or not to a rational post-operative follow-up with tumor markers 82
A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study 82
Bone remodeling, humoral networks and smart biomaterial technology for osteoporosis 82
Manual lymphatic drainage for chronic post-mastectomy lymphoedema treatment 81
Usefulness of a rationale post-operative follow-up of breast cancer with tumor markers 80
Low s.c. rIL-2 doses cyclically given in advanced renal cancer patients 80
intensive post operative follow of breast cancer patients with tumors markers: accuracy of serum MCA,Ca 15,3 and CEA, TPA,CA15.3 tumor maker panel for early detection of relapse. 80
Circulating tumor cells (CTCs) in breast cancer post-operative follow-up: a preliminary comparison with serum CEA-TPA-CA15.3 tumor marker (TM) panel based monitoring. 80
Home therapy with low-dose s.c. rIL-2 cycles to prolong the response to 5-FU and leucovorin (LV) in metastatic colorectal cancer 79
Metastatic colo rectal cancer : a pilot study with multistep therapy. 79
Cell mediated immunity in breast cancer patients 79
Our experience with subcutaneous (s.c.) rIL2 therapy in advanced cancer patients 78
TSH levels are affected by time of blood sampling in the follow up of levothyroxine substitution therapy: preliminary report 78
In colorectal cancer a multistep therapy with subcutaneous (s.c.) low dose recombinant interleukin-2(rIL-2),5-fluorouracil (5-FU) and leucovorin(LV) prolongs the duration of responce and overall survival of patients with inoperable metastases 78
CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis. 78
Methodological and clinical progress in thyroid tumor markers 77
Immunological and side effects of low sc recombinant interleukin-2 dose in addition to conventional treatment in relapsed breast and colorectal cancer patients 77
RELATIONSHIP AMONG CIRCULATING LEVELS OF THYROID HORMONES TSH AND TBG AFTER THYROIDECTOMY 76
Preoperative histological diagnosis of palpable thyroid nodules: accuracy of aspiration needle biopsy 76
In colorectal cancer a multistep therapy with subcutaneous (s. c.) low dose recombinant interleukin-2 (rIL-2), 5-fluorouracil (5-FU) and leucovorin (LV) prolongs the duration of response and overall survival of patients with inoperable metastases 76
T-cell mediated immunity, eosinophiles, SIL-2R, neopterin and interleukins 4,6,10,12 in metastatic renal and colorectal cancer patients clinically treated with low subcutaneous RIL-2 76
Serum tumor markers in the management of ovarian, endometrial and cervical cancer 76
Cytokines in the management of high risk or advanced breast cancer: an update and expectation 76
Restaging after neoadjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PET 76
Early detection of colorectal cancer relapses with tumor markers 75
Plasmatic parameters of coagulation activation in thrombotic microangiopathy 75
Large needle aspiration biopsy results of palpable thyroid nodules diagnosed by fine-needle aspiration as a microfollicular nodule with atypical cells or suspected cancer 75
Metastatic breast cancer: an updating 75
Percutaneous large-needle aspiration biopsy histology of palpable thyroid nodules: technical and diagnostic performance 75
Usefulness of “early” detection of colorectal cancer relapses with tumor markers 74
Comparison between hydroxyproline (OHP) and deoxypyridinoline (DPD) in the detection of bone metastases in patients with breast cancer 74
Totale 9.221
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.164
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.164
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.790 407 267 102 165 279 297 356 197 276 185 219 40
2020/20211.233 128 61 119 30 168 45 86 165 67 103 54 207
2021/20221.942 3 157 15 79 406 312 23 79 124 37 52 655
2022/20232.324 323 178 132 220 295 372 18 188 424 9 140 25
2023/20242.001 351 251 253 114 273 346 23 52 39 21 36 242
2024/20258 8 0 0 0 0 0 0 0 0 0 0 0
Totale 16.089